Person‐centered care through integration of services and engaging clients in their own care is essential to achieving epidemic control of HIV. Verticalization of services along the care continuum contributes to inequities in access to care and leads to stigma and discrimination.
The National Strategic Plan for HIV, TB and STIs (NSP) 2017-2022 Mid Term Review (MTR) was an in-depth analysis of the NSP implementation, with the aim to illustrate progress made towards reaching the NSP targets across the eight NSP goals.
Scientists who announced the discovery of a new subtype of HIV earlier this month are telling people not to worry: The discovery, they say, is a good thing and shows that the technology used to make it will improve surveillance of the (admittedly, mutating) virus, but it doesn't mean that HIV wil
In 2017, tuberculosis caused an estimated 1·6 million deaths, including 300 000 deaths among people with HIV, and surpassed HIV/AIDS to become the leading infectious cause of mortality worldwide. Approximately 36% of tuberculosis cases each year (around 3·5 million cases) are not diagnosed or rep
he GeneXpert MTB/RIF Assay (Xpert(R)) is known to be a feasible, effective and a hopeful tool for rapid tuberculosis (TB) diagnosis and treatment. However, little is known about the time delay caused by initial negative sputum smear microscopy (NSSM), but consecutive positive Xpert TB test (PXTBt) and its association with TB mortality in resource-constrained settings. We aimed to estimate the median time delay between initial NSSM but consecutive PXTBt and TB treatment initiation and its association with TB mortality among TB/HIV co-infected patients in Beira, Mozambique.
Subclinical tuberculosis is an asymptomatic disease phase with important relevance to persons living with HIV. We describe the prevalence, clinical characteristics, and risk of mortality for HIV-infected adults with subclinical tuberculosis.
The diagnostic accuracy of Xpert MTB/RIF is well documented, anticipated improvements in patient outcomes have not been clearly identified. We performed an individual patient data meta-analysis to examine improvements in patient outcomes associated with Xpert MTB/RIF.